Restrictive Intraoperative Fluid Rate is Associated with Improved Outcomes in Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

被引:5
|
作者
Peng, June S. [1 ,2 ]
LaPiano, Jessica [3 ]
Wang, Katy [4 ]
Attwood, Kristopher [4 ]
Skitzki, Joseph J. [5 ]
Kane, John M., III [1 ]
Francescutti, Valerie A. [1 ,5 ]
机构
[1] Roswell Pk Comprehens Canc Ctr, Dept Surg Oncol, Buffalo, NY 14203 USA
[2] Penn State Univ, Div Surg Oncol, Coll Med, Dept Surg, Hershey, PA 16801 USA
[3] Univ Buffalo, Jacobs Sch Med & Biomed Sci, Buffalo, NY USA
[4] Roswell Pk Comprehens Canc Ctr, Dept Biostat & Bioinformat, Buffalo, NY USA
[5] McMaster Univ, Dept Surg, Hamilton, ON, Canada
关键词
MORBIDITY; THERAPY; TRIAL;
D O I
10.1245/s10434-021-10556-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Management of patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CS/HIPEC) has historically favored liberal fluid administration owing to lengthy duration of surgery and hyperthermia. This practice has been challenged in recent years with studies demonstrating improved outcomes with restrictive fluid administration. Methods Patients who underwent CS/HIPEC between March 2010 and September 2018 were included for analysis. Patients who received an above-median fluid rate (high-IVF) versus below-median fluid rate (low-IVF) were compared, and multivariate analyses were performed for length of stay, 90-day unplanned readmissions, and major complications. Results The 167 patients had a mean age of 56.7 +/- 11.4 years and body mass index of 29.5 +/- 6.9 kg/m(2). The median rate of total intraoperative crystalloid and colloid was 7.4 mL/kg/h. The low-IVF group had less blood loss (183 vs. 330 mL, p = 0.002), were less likely to need intraoperative vasopressor drip (2.4% vs. 11.9%, p = 0.018), and experienced fewer cardiac complications (2.4% vs. 10.7%, p = 0.031), pneumonias (0% vs. 6.0%, p = 0.024), and Clavien-Dindo grade 3-5 complications (14.5% vs. 33.3%, p = 0.004). Multivariate analyses identified bowel resection (HR 4.65, p = 0.0008) as a risk factor for 90-day unplanned readmission, while bowel resection, intraoperative fluid rate, and estimated blood loss were associated with increased length of stay. Conclusion Higher intraoperative fluid intake was associated with multiple postoperative complications and increased length of stay, and represents a potentially avoidable risk factor for morbidity in CS/HIPEC.
引用
收藏
页码:163 / 173
页数:11
相关论文
共 50 条
  • [41] Morbidity and Mortality Outcomes After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer
    Kim, Migang
    Lee, Yong Jae
    Seon, Ki Eun
    Kim, Sunghoon
    Lee, Chan
    Park, Hyun
    Choi, Min Chul
    Lee, Jung-Yun
    JOURNAL OF CLINICAL MEDICINE, 2025, 14 (05)
  • [42] Outcomes Associated With Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy in Colorectal Cancer Patients With Peritoneal Surface Disease and Hepatic Metastases
    Varban, Oliver
    Levine, Edward A.
    Stewart, John H.
    McCoy, Thomas P.
    Shen, Perry
    CANCER, 2009, 115 (15) : 3427 - 3436
  • [43] Impact of Depression in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy With Cytoreductive Surgery
    de Boissieu, Paul
    Crespel, Celine
    Duminil, Laura
    de Mestier, Louis
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (28) : 3482 - +
  • [44] Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in treatment of peritoneal metastasis
    Sokmen, Selman
    Bisgin, Tayfun
    Manoglu, Berke
    Altay, Canan
    Ellidokuz, Hulya
    TURKISH JOURNAL OF SURGERY, 2022, 39 (01) : 43 - 51
  • [45] Hepatobiliary Procedures in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
    Glockzin, Gabriel
    Renner, Philipp
    Popp, Felix C.
    Dahlke, Marc H.
    von Breitenbuch, Philipp
    Schlitt, Hans J.
    Piso, Pompiliu
    ANNALS OF SURGICAL ONCOLOGY, 2011, 18 (04) : 1052 - 1059
  • [46] Cytoreductive onco-surgery with combined hyperthermic intraperitoneal chemotherapy and hyperthermic intrathoracic chemotherapy: Perioperative challenges
    Dattatri, Rohini
    Garg, Rakesh
    Ray, Mukur Dipi
    SAUDI JOURNAL OF ANAESTHESIA, 2019, 13 (02) : 131 - 135
  • [47] Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Mesothelioma
    Tan, Grace H. C.
    Cheung, Michelle
    Chanyaputhipong, Jendana
    Soo, Khee Chee
    Teo, Melissa C. C.
    ANNALS ACADEMY OF MEDICINE SINGAPORE, 2013, 42 (06) : 291 - 296
  • [48] The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery
    Kusamura, Shigeki
    Barretta, Francesco
    Yonemura, Yutaka
    Sugarbaker, Paul Hendrick
    Moran, Brendan John
    Levine, Edward A.
    Goere, Diane
    Baratti, Dario
    Nizri, Eran
    Morris, David Lawson
    Glehen, Olivier
    Sardi, Armando
    Barrios, Pedro
    Quenet, Francois
    Villeneuve, Laurent
    Gomez-Portilla, Alberto
    de Hingh, Ignace
    Ceelen, Wim
    Pelz, Joerg O. W.
    Piso, Pompiliu
    Gonzalez-Moreno, Santiago
    van der Speeten, Kurt
    Deraco, Marcello
    JAMA SURGERY, 2021, 156 (03)
  • [49] Safety of rectum anastomosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    von Breitenbuch, Philipp
    Piso, Pompiliu
    Schlitt, Hans J.
    JOURNAL OF SURGICAL ONCOLOGY, 2018, 118 (03) : 551 - 556
  • [50] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Technical considerations and the learning curve
    Vining, Charles C.
    Izquierdo, Francisco
    Eng, Oliver S.
    Turaga, Kiran K.
    JOURNAL OF SURGICAL ONCOLOGY, 2020, 122 (01) : 85 - 95